Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Tandem Diabetes securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Company Incident and Stock Impact - On August 7, 2025, Tandem Diabetes issued a press release regarding a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

Company Overview - Flowserve is a leading provider of flow management solutions with a global footprint and a diversified customer base [7] - The company generates revenue from the sale of engineered products and aftermarket services, serving critical infrastructure sectors such as oil and gas, chemical and pharmaceuticals, power generation, water management, and general industrial markets [9] - Key financial metrics include revenue of $4.69 billion, net income of $452.78 million, and a dividend yield of 1.09% [5] Recent Developments - On January 28, 2026, Paradice Investment Management LLC disclosed a purchase of 178,356 shares of Flowserve, valued at an estimated $11.46 million based on quarterly average pricing [1][2] - This purchase increased Flowserve's stake to 6.98% of Paradice's reportable 13F assets under management [3] - The fund's quarter-end position in Flowserve rose in value by $17.87 million, reflecting both trading activity and stock price changes [2] Stock Performance - As of January 28, 2026, Flowserve shares were priced at $76.90, representing a 28.49% increase over the past year, outperforming the S&P 500 by 12 percentage points [4] - Paradice originally purchased Flowserve stock at $53 per share in Q3 and increased its position at $69 in Q4, indicating strong confidence in the stock's potential [10]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Tandem Diabetes securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - A class action is being prepared by Rosen Law Firm to seek recovery of investor losses [2]. Group 2: Company Incident and Stock Impact - On August 7, 2025, Tandem Diabetes issued a press release regarding a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering substantial amounts for clients [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Information - Tandem Diabetes Care, Inc. is facing scrutiny after a press release on August 7, 2025, announced a voluntary medical device correction for select t:slim X2 insulin pumps, which could lead to a discontinuation of insulin delivery due to a speaker-related issue [3]. - Following the announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 2: Legal Actions - Investors who purchased Tandem Diabetes securities may be eligible for compensation through a class action lawsuit being prepared by Rosen Law Firm, with no out-of-pocket fees required [2]. - Interested investors can join the class action by submitting a form or contacting the law firm directly for more information [2]. Group 3: Rosen Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

Core Insights - ViCentra, a European medical device company, has completed a second close of its Series D funding round, raising an additional $13 million, bringing the total to $98 million (approximately 680 million RMB) [2][3] - The new funding will primarily be used to expand manufacturing capabilities, enhance commercialization efforts in Germany, the Netherlands, and France, and accelerate preparations for the next-generation Kaleido insulin patch pump system's entry into the U.S. market [3][5][6] Funding Utilization - The additional funds will be allocated to three main areas: 1. Expansion of manufacturing capacity to meet growing market demand and support future regional expansion [5] 2. Deepening commercialization efforts in core European markets, particularly Germany, which is the second-largest insulin pump market globally [5][6] 3. Preparing for market entry in the U.S., a competitive but large insulin delivery market [6] Product Focus - ViCentra's core product is the Kaleido insulin patch pump system, designed as a wearable insulin delivery device that combines medical performance with personal technology attributes [7][9] - The Kaleido system is noted for being one of the smallest, lightest, and most precise delivery systems in its category, featuring an aluminum casing and offering up to 10 color options [9] Market Environment - The insulin delivery device market is entering a new phase of technological and product replacement, with patch pumps becoming one of the fastest-growing segments due to their flexibility and ease of use [11][12] - In Europe, the market dynamics differ from the U.S., with a focus on long-term treatment costs and sustainability, favoring products with durability and material advantages [13] - The integration of automated insulin delivery systems (AID) with continuous glucose monitoring (CGM) systems is becoming a significant competitive factor, shifting the market focus from hardware performance to comprehensive system capabilities [13]

Core Viewpoint - Tandem Diabetes Care, Inc. is a prominent player in the insulin pump technology market, showing resilience against competition from major companies like Medtronic and Insulet Corporation [1] Company Performance - RBC Capital maintains an "Outperform" rating for Tandem Diabetes, raising its price target from $25 to $30, reflecting confidence in the company's growth potential [2] - The average twelve-month price target from brokerages is approximately $22.44, slightly below the current stock price of $23.03, indicating a modest increase of 1.90% or $0.43 [3] Analyst Sentiment - Analyst ratings for Tandem Diabetes show mixed sentiment: one "sell," eleven "hold," and five "buy" recommendations [3] - Stifel Nicolaus initiated coverage with a "hold" rating and a target price of $15.00, while Canaccord Genuity reaffirmed a "buy" rating with a price objective of $24.00 [4] Stock Performance - The stock has fluctuated between a low of $22.40 and a high of $23.10 during the day, with a yearly peak of $38.28 and a low of $9.98 [5] - Tandem Diabetes Care has a market capitalization of approximately $1.56 billion and a trading volume of 120,728 shares on the NASDAQ exchange [5]

Core Viewpoint - Tandem Diabetes Care is facing significant challenges, with a 43% decline in share price, and while it has innovative products, it needs to achieve consistent revenue growth to become an attractive investment [2][6]. Company Overview - Tandem Diabetes Care is a medical device company known for its innovative insulin pumps, particularly the t:slim X2, which has been a key growth driver [4]. - The company launched the Tandem Mobi, a smaller device that can be controlled via a smartphone app, in the U.S. last year [5]. Financial Performance - Despite its innovative offerings, Tandem Diabetes Care has experienced declining revenue growth over the past five years due to competition and lower demand for insulin pumps [5]. - The company remains unprofitable, and the current global trade environment may worsen its financial situation, particularly due to reliance on imported parts from countries like Mexico and China [6][8]. - The market capitalization of Tandem Diabetes Care is approximately $1 billion, with a gross margin of 53.23% [8]. Growth Potential - For Tandem Diabetes Care to be considered a viable investment, it needs to achieve mid-to-high teens revenue growth by expanding market share and encouraging current users to upgrade their devices [9]. - The introduction of the Tandem Mobi and other products in development could contribute to this growth strategy [10]. Investment Outlook - Currently, the stock is not recommended for purchase due to inconsistent revenue growth, competitive pressures, and industry challenges that may hinder profitability [10].

Core Insights - Tandem Diabetes Care, Inc. (TNDM) is experiencing significant international expansion, which is expected to enhance growth in upcoming quarters. The company's strategic initiatives present favorable growth opportunities, although there are concerns regarding its heavy reliance on insulin pumps and the impact of macroeconomic challenges [1][9]. Financial Performance - Over the past year, TNDM's shares have declined by 38.7%, while the industry saw a minor decline of 0.3%. In contrast, the S&P 500 composite has increased by 16.4% during the same period. The company has a market capitalization of $1.15 billion and projects a growth rate of 59.2% for 2026 earnings, compared to 14.7% for the S&P 500 [2]. Strategic Developments - Tandem Diabetes is focusing on growth through acquisitions and investments in new technologies. The company has a competitive edge due to its rapid integration of Continuous Glucose Monitoring (CGM) systems, supported by partnerships with Dexcom and Abbott. The t:slim X2 pump is now compatible with Eli Lilly's ultra-rapid-acting insulin, Lyumjev [3][5]. - Operational improvements are being implemented to enhance efficiency, including streamlining processes and increasing automation. In Q3, Tandem achieved significant milestones by expanding pharmacy benefit coverage for Tandem Mobi to over 40% of U.S. covered lives and began selling t:slim supplies through pharmacy benefits [4]. International Market Focus - The International Diabetes Federation projects that by 2030, around 643 million people globally will have diabetes. Tandem's international expansion strategy aligns with this trend, allowing the company to capitalize on substantial market opportunities. In Q3, revenues outside the U.S. increased by 1.8% year-over-year, with approximately 9,000 pumps shipped across 25 markets [5][6][8]. Challenges - Macroeconomic uncertainties pose challenges for TNDM, making it difficult to predict product demand accurately. These conditions could lead to increased expenses and negatively affect financial performance. In Q3, the company reported a net loss of $21.2 million [9]. - TNDM's heavy dependence on insulin pumps is a concern, as these products accounted for 44.2% of worldwide sales in Q3 2025. Factors affecting market acceptance among insulin-dependent diabetes patients and healthcare providers could hinder the company's business and financial results [10]. Revenue Estimates - The Zacks Consensus Estimate for TNDM's 2025 loss per share has narrowed by 5 cents to $2.35 over the past 30 days. Revenue estimates for 2025 are projected at $1.00 billion, indicating a 9.9% increase from the previous year [11].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Information - Tandem Diabetes Care, Inc. issued a press release on August 7, 2025, announcing a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following the announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 2: Legal Actions - Investors who purchased Tandem Diabetes Care securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 3: Rosen Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

Tandem Diabetes Care FY Conference Summary Company Overview - **Company**: Tandem Diabetes Care (NasdaqGM:TNDM) - **Date of Conference**: December 02, 2025 Key Industry Insights - **Industry**: Diabetes care technology, specifically focusing on insulin delivery systems and related supplies Core Points and Arguments 1. **Pricing Strategy and Revenue Growth** - Pricing contributed to a 5% revenue growth in Q3, primarily from domestic sales [2][12] - Two-thirds of the pricing benefit came from pharmacy sales, with one-third from Durable Medical Equipment (DME) [5][7] - The company anticipates that pricing strategies could lead to significant revenue increases, potentially reaching $500 million in supplies alone based on current pricing benefits [23][28] 2. **Market Coverage and Expansion** - Tandem currently has 40% coverage of U.S. lives for MobiPump and supplies, with rapid growth expected [14][16] - The company aims to transition existing patients from DME to pharmacy channels, which is crucial for maximizing revenue [20][21] 3. **Gross Margin Improvement** - Gross margins improved to between 53%-54% in Q3, with expectations to reach 60% by the end of 2026 [28][30] - Price increases are a major driver of this improvement, enhancing both top-line and bottom-line growth [26][28] 4. **Product Innovation and Market Positioning** - Tandem is focusing on expanding its product offerings, including the upcoming tubeless Mobi pump and a fully closed-loop system expected to start pivotal trials in 2026 [67][68] - The company is also integrating with Android and FreeStyle Libre 3, expanding its addressable market [41][42] 5. **Competitive Landscape** - Tandem is positioned to compete effectively against other players in the market, such as Insulet and Medtronic, by leveraging its superior algorithm and product features [30][43] - The company acknowledges the challenges posed by competitors but believes its product offerings will resonate well with both patients and healthcare providers [43][52] 6. **Financial Performance and Future Outlook** - Tandem returned to EBITDA positive in Q3, with a goal to maintain positive EBITDA annually moving forward [80][81] - The company generated $50 million in EBITDA in 2022 and aims to reach that level again as early as next year [83][84] Additional Important Insights - **Patient Engagement**: The company is actively working to engage physicians and patients to facilitate the transition to pharmacy channels, which is critical for maximizing the benefits of pricing strategies [20][21] - **Market Growth**: The overall pump market is expected to grow at double-digit rates, driven by new technologies and the expansion of the type 2 diabetes market [78][75] - **Sales Force Optimization**: Tandem has expanded its sales force to better target high prescribers of insulin, ensuring efficient market penetration for its new products [72][73] This summary encapsulates the key points discussed during the Tandem Diabetes Care FY Conference, highlighting the company's strategic focus on pricing, market expansion, product innovation, and financial performance.